OPERATIONAL TECHNOLOGIES CORPORATION

Biotech

DNA aptamers that block oxidized linoleic acid metabolites (OLAMs) to modulate TRPV1 pain signaling

Grants
$1.5M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Agriculture · Fluorescent Dna Aptamer Test Strips For More Sensitive And Rapid Assessment Of Food Safety.$99,977
Federal grantDepartment of Health and Human Services · Phase II · Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)$534,504
Federal grantDepartment of Agriculture · Fluorescent Aptamer Test Strips For Food Safety Testing$439,867
Federal grantDepartment of Health and Human Services · Phase II · Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)$464,965
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1113JUN INNOVATIONS INC——
1114COMPANION SCIENCES, INC.——
1115Mu Therapeutics Inc.——
1116OPERATIONAL TECHNOLOGIES CORPORATION——
1117NUTRASORB LLC——
1118FGF Therapeutics INC.——
1119DURAVAX INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.